Pfizer Announces 3rd COVID Vaccine for Children is 80% Effective

Pfizer Announces 3rd COVID Vaccine for Children is 80% Effective 

  • Pfizer has announced that the third dose of its COVID vaccine for children elicited a strong immune response.
  • The company claims that a third shot can prevent illness from Omicron by up to 80%.
  • The company has requested authorisation for vaccine administration for children below 5 in the United States.

Pfizer and BioNTech’s three-dose Covid vaccine for children has been shown to be 80% effective at preventing illness from the Omicron variant. This report was given based on clinical trial results carried out during the omicron wave.

The report claims that a third dose of the vaccine elicited a strong immune response among children between 6 months and 5 years.

The safety data is based on trials on 1,678 children under age 5. The children received a third shot of the vaccine at least two months after the second dose.

The kids received 3-microgram shots, one-tenth the dosage level for adults and Pfizer examined some of the children to determine their immune response.

BioNTech CEO Ugur Sahin said that the two companies plan to complete their application to the Food and Drug Administration for the authorisation of the vaccine for children. Meanwhile, Pfizer CEO Albert Bourla, says that he hopes that the vaccine will be available to younger kids as soon as possible.

Read also: Sniffer Dogs Trained to detect COVID infection in people

Pfizer and the Food and Drug Administration had originally sought to authorise the COVID vaccine for children in February. However, the application was later delayed to wait on data from the administration of the third dose. This was due to the first two shots being only 30% to 40% effective against Omicron.

COVID vaccine for children

Currently, children under age 5 are the only group not eligible for vaccination in the U.S.

Follow on our social media handles FacebookInstagram, and Twitter to keep up with trending news and entertainment gist.

Show More

Related Articles

Back to top button